leadf
logo-loader
viewKintara Therapeutics

Kintara expects to enroll first GBM patient in Phase 3 clinical trial by late 2020/early 2021

Kintara Therapeutics, Inc. (NASDAQ:KTRA) CEO Saiid Zarrabian talks to Proactive about upcoming milestones for the San Diego-based biopharmaceutical company.

Zarrabian says namely, it expects to enroll its first glioblastoma multiforme (GBM) patient in a Phase 3 clinical trial using its lead compound VAL-083 by late 2020/early 2021.

Quick facts: Kintara Therapeutics

Price: 1.71 USD

NASDAQ:KTRA
Market: NASDAQ
Market Cap: $52.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

HempFusion submits application to the Uk’s Food Regulatory body for product...

HempFusion (TSE: CBD- OTCQX: CBDHF) CEO Jason Mitchell joined Steve Darling from Proactive to share news the company has submitted its dossier to the United Kingdom's Regulatory Food Safety Agency. Mitchell telling Proactive the first step in the United Kingdom’s regulatory approval process...

13 hours, 45 minutes ago

2 min read